Skip to main content

Table 4 Comparison of the main adverse events and antithrombotic therapy according to the region of CMBs

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

  Region of CMBs χ2 P value
Brain lobe n = 42 Deep brain tissue n = 50 Mixed region n = 18
Antithrombotic therapy
 Anticoagulant therapy (%) 20 (47.6) 20 (40.0) 14 (77.8) 7.617 0.022
 Antiplatelet therapy (%) 22 (52.4) 30 (60.0) 4 (32.2)   
CH events (%) 8 (19.0) 6 (12.0) 4 (22.2) 1.368 0.505
All-cause death (%) 2 (4.8) 8 (16.0) 4 (22.2) 4.342 0.114